Latest news and press releases about Biodesix, Inc. (BDSX): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Biodesix, Inc. is a data-driven diagnostic solutions provider operating across the United States. Its primary focus includes a comprehensive suite of blood-based lung tests, marketed as the Nodify Lung Nodule Risk Assessment (which includes Nodify XL2 and Nodify CDT). These assessments enable clinicians to evaluate the risk of lung cancer in patients with suspicious nodules, aiding in the reclassification of malignancy risk and guiding appropriate treatment pathways.
Price
| Price | $28.56 |
| Market Cap | $232M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 32.11 |
| EV / EBITDA | -17.85 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -788.19% |
| Return on Invested Capital | -25.22% |
| Return on Assets | -29.12% |
| Gross Margin | 82.50% |
| Operating Margin | -20.01% |
| Net Margin | -26.97% |
Related companies: ALGS · INMB · MRSN · NOTV · OKUR · PDSB · SKYE
Explore sector: Healthcare · Medical - Diagnostics & Research
More sections of BDSX: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks